AUTHORS
Uma Borate, MBBS, MSc, Megan Othus, PhD2, Jayanshu Jain, MD3, Catherine Lai, MD, MPH4, Manu Pandey, MBBS5, Laura C Michaelis, MD6, Anna Moseley, MS7, Brent Wood, MD, PhD8, Min Fang, MD, PhD, FACMG9, Jerald Radich, MD10, Cecilia CS Yeung, MD, Professor Pathology11, Shahanawaz Jiwani, MBBS, PhD12, Steven Gore, MD13, Richard F. Little, MD14, Mark R. Litzow, MD15, Geoffrey L. Uy, MD16, Harry Erba, MD, PhD17
AFFILIATIONS
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 University of Pennsylvania, Philadelphia, Washington, United States
5 University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 SWOG Statistics and Data Management Center, Seattle, Washington, United States
8 University of Southern California, Los Angeles, California, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States
13 National Institute of Health, Bethesda, Maryland, United States
14 National Institute of Health, Bethesda, Maryland, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Washington University School of Medicine, St. Louis, Missouri, United States
17 Duke University, Durham, North Carolina, United States
ABSTRACT
Background and Significance: Treatment for older and unfit adults with acute myeloid leukemia (AML) consists of venetoclax in combination with a DNA methyltransferase inhibitor (DNMTi). While targeted therapies are being developed and incorporated into frontline treatments in AML, most older adults do not have targetable mutations and continue to receive venetoclax (VEN) with DNMTi as standard treatment. This standard-of-care was initially set by VIALE-A which demonstrated an overall survival benefit of VEN with azacitidine (AZA) compared with AZA alone. The phase 1-2 study ASCERTAIN-V recently led to the approval of the all oral regimen of venetoclax with ASTX727 (decitabine-cedazuridine), with comparable rates of complete remission as VEN/AZA.
When used in combination with a DNMTi, VEN is given daily for 28 days; however, prolonged myelosuppression has been seen with this combination and optimal dosing remains an ongoing challenge in clinical care. In VIALE-A and ASCERTAIN-V, most patients (pts) required shorter duration of VEN in subsequent cycles to mitigate ongoing hematologic toxicity of treatment. Retrospective analyses have suggested that VEN duration can be reduced without affecting efficacy, including analyses of VEN given for 7, 14, or 21 days rather than the standard 28 days.
OPTI-AML was a prospective, randomized phase 2 trial comparing VEN for 28 versus 14 days in combination with AZA, with a primary endpoint of complete remission after 2 cycles. In this study, non-inferiority was not shown, but was complicated by an imbalance in pts with VEN-sensitive mutations (NPM1, IDH1/2) receiving VEN for 28 days and many pts receiving less than the full duration of VEN assigned. Additionally, data regarding treatment beyond 2 cycles was not available, limiting assessment of longer-term outcomes. As such, questions still remain regarding the optimal duration of VEN when combined with a DNMTi.
Study Design and Methods: myeloMATCH (Myeloid Malignancies Molecular Analysis for Therapy Choice) is a National Cancer Institute–led precision medicine platform trial that uses rapid genomic profiling to match pts with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to biomarker-driven treatment substudies. Subjects are enrolled onto the myeloMATCH Master Screening and Reassessment Protocol (NCT05564390) and are then assigned to MM1OA-S04 (NCT07437950) if eligible.
MM1OA-S04 is a phase 2 trial enrolling pts who are at least 60 years old with newly diagnosed AML, who are thought to be unfit for intensive chemotherapy as determined by the treating physician. Pts must have an ECOG performance status of 0-3 along with adequate cardiac, liver, and renal function. Pts are excluded if they have acute promyelocytic leukemia (APL) or have mutations in FLT3-ITD, FLT3-TKD, or TP53. Participants will be randomized to receiving VEN for 28 days (VEN-28) in combination with ASTX727 versus VEN for 14 days (VEN-14) in combination with ASTX727. This randomized hybrid design will require 120 eligible participants (60 per arm), with up to 126 enrolled to account for 5% of participants being ineligible or not evaluable. Of note, a substudy for pts with IDH2-mutated AML is currently open (MM1OA-S03, NCT06672146) and a trial for older pts with NPM1-mutated AML is expected to activate in late 2026, so these genomic features are anticipated to be infrequent in MM1OA-S04.
The primary endpoint will compare rates of measurable residual disease (MRD) negative complete remission (CR) at 180 days between the two arms, with MRD measured by flow cytometry. This will be tested hierarchically, first by assessing that VEN-14 is not 12% worse than VEN-28 and if VEN-14 is non-inferior, then by testing if VEN-14 is superior to VEN-28. Pts can proceed to allogeneic stem cell transplant at any time, with MRD negative CR to be assessed on a pre-transplant bone marrow biopsy. An interim futility analysis will be performed after the first 60 eligible participants have undergone primary endpoint assessment. Secondary endpoints include assessment of cycles completed, dose reductions or treatment delays, toxicity, response rates, survival, and mechanisms of resistance and sensitivity to treatment.
MM1OA-S04 is a multisite, pan-NCTN study activated in July 2026 and is anticipated to enroll subjects through July 2029. The study will soon begin enrolling in the United States.
DISCLOSURES
Jayanshu Jain, MD: Geron - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)